Cell Death and Disease Submission Guide

Source: Clarivate JCR 2024, Springer Nature editorial disclosures (accessed April 2026).

Source: Cell Death and Disease author guidelines.

Use this page when deciding:

• whether the disease-mechanism contribution is substantive
• whether functional validation is rigorous
• whether translational relevance is direct

• a clear disease-mechanism contribution
• rigorous functional validation
• in-vivo or clinical validation
• translational relevance
• a cover letter establishing the contribution

• Descriptive cell-death observations without disease relevance.
• Weak functional or in-vivo validation.
• Missing translational connection.
• Basic cell biology without disease focus.

Cell Death and Disease is a flagship cell-death-in-disease journal.

Disease-focus standard: the journal differentiates from Cell Death and Differentiation (basic cell-death biology) by demanding disease relevance.

Functional and in-vivo expectation: editors expect functional and in-vivo or clinical evidence.

The 30-40% desk rejection rate: decisive editorial screen.

The strongest Cell Death and Disease cover letters establish:

• the disease-mechanism contribution
• the functional validation
• the in-vivo or clinical evidence
• the translational relevance

• Is Cell Death and Disease a good journal?
• Cell Death and Differentiation submission guide

Before upload, run your manuscript through a Cell Death and Disease mechanism readiness check.

In our pre-submission review work with cell-death-disease manuscripts targeting Cell Death and Disease, three patterns generate the most consistent desk rejections.

In our experience, roughly 35% of Cell Death and Disease desk rejections trace to descriptive observations without disease relevance. In our experience, roughly 25% involve weak functional validation. In our experience, roughly 20% arise from missing in-vivo or clinical validation.

• Descriptive cell-death observations without disease relevance. Cell Death and Disease editors look for disease mechanism, not just basic observations. We observe submissions reporting only cell-death pathway data without disease connection routinely desk-rejected.

• Weak functional or in-vivo validation. Editors expect functional evidence and in-vivo or clinical validation. We see manuscripts with thin functional experiments routinely returned.

• Missing translational connection. Cell Death and Disease specifically expects translational relevance. We find papers framed as basic cell biology without disease application routinely declined. A Cell Death and Disease mechanism readiness check can identify whether the package supports a submission.

Clarivate JCR 2024 bibliometric data places Cell Death and Disease among top cell-death-disease journals.

In pre-submission diagnostic work for top cell-death-disease journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the contribution must link cell death to specific disease. Second, functional validation should be rigorous. Third, in-vivo or clinical validation should be included. Fourth, translational relevance should be direct.

The single most consistent feedback class we deliver in pre-submission diagnostics for Cell Death and Disease is the basic-versus-disease-mechanism distinction. Cell Death and Disease editors expect disease relevance. Submissions framed as "we observed cell-death pathway X" routinely receive "where is the disease?" feedback during desk screening. We coach authors to lead with the disease question. Papers framed as "we tested whether cell-death mechanism X drives disease phenotype Y by combining functional, genetic, in-vivo, and patient-sample analysis" receive better editorial traction. The same logic applies across disease-focused cell-death journals: editors are operating with limited slot inventory.

Beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Cell Death and Disease. First, manuscripts where the abstract reports cell-death observations without articulating the disease connection are flagged for descriptive framing. Second, manuscripts where in-vivo data is reported only in supplementary materials are flagged for translational framing gaps. Third, manuscripts that lack engagement with Cell Death and Disease's recent issues are at risk of being told the contribution doesn't fit the publication conversation.

The strongest manuscripts we coach distinguish themselves on three operational behaviors. First, they confine the cover letter to one page. Second, they include a one-sentence elevator pitch. Third, they identify the specific recent papers in the journal that this manuscript builds on.